Status:
COMPLETED
The Efficacy of N-acetylcysteine Versus Placebo for the Treatment of Metamphetamine Withdrawal Symptoms
Lead Sponsor:
Melva Louisa
Conditions:
Methamphetamine Dependence in Remission
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
PHASE3
Brief Summary
Up to date, no approved medications are available for the treatment of methamphetamine addiction. Recently, N-acetylcysteine is recently being studied for methamphetamine withdrawal. N-acetylcysteine...
Detailed Description
Methamphetamine is a stimulant commonly abused worldwide. Methamphetamine can produce a rapid pleasurable rush caused by release of dopamine, nor-ephinephrine and serotonin. It produces euphoria, a he...
Eligibility Criteria
Inclusion
- Men or women, 18 - 60 years old
- Diagnosed with methamphetamine addiction based on DSM-V criteria, enrolling for methamphetamine withdrawal treatment
- Agree to participate in the trial by signing informed consent
Exclusion
- Known hypersensitivity to N-acetylcysteine
- Patients with serious conditions that will not allow protocol compliance or safe participation in the clinical trials.
- Pregnant or breastfeeding women
- History of suicidal thoughts / behaviour
- History of N-acetylcysteine treatment
- History of asthma and convulsions
Key Trial Info
Start Date :
October 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2020
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT04405193
Start Date
October 1 2019
End Date
December 30 2020
Last Update
February 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rehabilitation Center, National Narcotics Agency
Bogor, West Java, Indonesia, 16110